Anebulo Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 28.86

ANEB Stock  USD 1.38  0.19  12.10%   
Anebulo Pharmaceuticals' future price is the expected price of Anebulo Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Anebulo Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Anebulo Pharmaceuticals Backtesting, Anebulo Pharmaceuticals Valuation, Anebulo Pharmaceuticals Correlation, Anebulo Pharmaceuticals Hype Analysis, Anebulo Pharmaceuticals Volatility, Anebulo Pharmaceuticals History as well as Anebulo Pharmaceuticals Performance.
For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.
  
At present, Anebulo Pharmaceuticals' Price Book Value Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Earnings To Growth Ratio is expected to grow to 0.28, whereas Price Earnings Ratio is forecasted to decline to (8.86). Please specify Anebulo Pharmaceuticals' target price for which you would like Anebulo Pharmaceuticals odds to be computed.

Anebulo Pharmaceuticals Target Price Odds to finish over 28.86

The tendency of Anebulo Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 28.86  or more in 90 days
 1.38 90 days 28.86 
close to zero percent
Based on a normal probability distribution, the odds of Anebulo Pharmaceuticals to move over $ 28.86  or more in 90 days from now is close to zero percent (This Anebulo Pharmaceuticals probability density function shows the probability of Anebulo Stock to fall within a particular range of prices over 90 days) . Probability of Anebulo Pharmaceuticals price to stay between its current price of $ 1.38  and $ 28.86  at the end of the 90-day period is under 95 .
Given the investment horizon of 90 days Anebulo Pharmaceuticals has a beta of 0.86. This suggests Anebulo Pharmaceuticals market returns are sensitive to returns on the market. As the market goes up or down, Anebulo Pharmaceuticals is expected to follow. Additionally Anebulo Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Anebulo Pharmaceuticals Price Density   
       Price  

Predictive Modules for Anebulo Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Anebulo Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Anebulo Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.081.5310.17
Details
Intrinsic
Valuation
LowRealHigh
0.142.7911.43
Details
Naive
Forecast
LowNextHigh
0.031.7210.36
Details
1 Analysts
Consensus
LowTargetHigh
5.926.507.22
Details

Anebulo Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Anebulo Pharmaceuticals is not an exception. The market had few large corrections towards the Anebulo Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Anebulo Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Anebulo Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.04
β
Beta against Dow Jones0.86
σ
Overall volatility
0.27
Ir
Information ratio -0.0065

Anebulo Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Anebulo Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Anebulo Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Anebulo Pharmaceuticals generated a negative expected return over the last 90 days
Anebulo Pharmaceuticals has high historical volatility and very poor performance
Anebulo Pharmaceuticals may become a speculative penny stock
Net Loss for the year was (8.2 M) with profit before overhead, payroll, taxes, and interest of 0.
Anebulo Pharmaceuticals currently holds about 14.55 M in cash with (8.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62.
Anebulo Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 64.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Cunningham, Richard Anthony of 254433 shares of Anebulo Pharmaceuticals at 1.56 subject to Rule 16b-3

Anebulo Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Anebulo Stock often depends not only on the future outlook of the current and potential Anebulo Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Anebulo Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding25.8 M
Cash And Short Term Investments3.1 M

Anebulo Pharmaceuticals Technical Analysis

Anebulo Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Anebulo Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Anebulo Pharmaceuticals. In general, you should focus on analyzing Anebulo Stock price patterns and their correlations with different microeconomic environments and drivers.

Anebulo Pharmaceuticals Predictive Forecast Models

Anebulo Pharmaceuticals' time-series forecasting models is one of many Anebulo Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Anebulo Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Anebulo Pharmaceuticals

Checking the ongoing alerts about Anebulo Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Anebulo Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Anebulo Pharmaceuticals generated a negative expected return over the last 90 days
Anebulo Pharmaceuticals has high historical volatility and very poor performance
Anebulo Pharmaceuticals may become a speculative penny stock
Net Loss for the year was (8.2 M) with profit before overhead, payroll, taxes, and interest of 0.
Anebulo Pharmaceuticals currently holds about 14.55 M in cash with (8.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.62.
Anebulo Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Roughly 64.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Acquisition by Cunningham, Richard Anthony of 254433 shares of Anebulo Pharmaceuticals at 1.56 subject to Rule 16b-3
When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anebulo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.32)
Return On Assets
(0.66)
Return On Equity
(1.14)
The market value of Anebulo Pharmaceuticals is measured differently than its book value, which is the value of Anebulo that is recorded on the company's balance sheet. Investors also form their own opinion of Anebulo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Anebulo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anebulo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Anebulo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anebulo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anebulo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anebulo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.